Disallowed Procedures

For Board decisions on procedures and treatments which have been promulgated into rule, please see Administrative Rules of Montana, 24.29.1526, Disallowed Procedures.

At its March 27, 2009 meeting, the Board of Medical Examiners considered the status of Extreme Lateral Interbody Fusion (XLIA) and determined that it is experimental.

At its November 2007 meeting, the Board of Medical Examiners reviewed material regarding the Freezeframer device and determined that it is still in the investigative stage. The Board requests that three positive and three negative scientific articles be provided to it for another review when this information is available in the future.

At its July 27th, 2007 meeting, the Board of Medical Examiners considered the medical procedure Frequency Specific Microcurrent and determined it to be experimental at this time.

At its December 2006 meeting, the Board of Medical Examiners determined that the combined use of the HEALOS/Leopard Cage is an experimental protocol at this time.

On July 27th, 2007, the Board of Medical Examiners determined the procedure Inter X Therapy to be experimental at this time.

On March 2007, the Board moved to disapprove the use of kinesis myofascial integration at this time, finding that there is not enough evidence to support it. The Board moved unanimously to consider kinesis myofascial integration to be experimental.

At its March 27, 2009 meeting, the Board of Medical Examiners considered the status of Lidoderm Patch and determined the materials presented were inconclusive and that the Board could not make a definitive statement about it.

At its July 23, 2010 meeting, the Board of Medical Examiners considered the status of Medical Marijuana and unanimously voted that the Board does not have a sufficient, supportive body of evidence to recommend the use of medical marijuana in cases under the jurisdiction of the Montana Workers' Compensation Program.

At it's July 24, 2009 meeting, the Montana Board of Medical Examiners considered the material regarding Percutaneous Disc Nucleoplasty and determined that it is experimental and investigational for treating back pain and other indications. The review complies with the provisions of 39-71-704(1)(g), MCA, which states, “Notwithstanding any other provisions of this chapter, the department, by rule and upon the advice of the professional licensing boards of practitioners affected by the rule, may exclude from compensability any medical treatment that the department finds to be unscientific, unproved, outmoded, or experimental.”

Refer to the U & T Guidelines link for treatments and procedures not listed here

Medical Regulations Administrative Officer

• Celeste Ackerman (celeste.ackerman@mt.gov or 406-444-1389)